🇺🇸 FDA
Pipeline program

SPD602

SPD602-203

Phase 2 small_molecule terminated

Quick answer

SPD602 for Iron Overload Due to Repeated Red Blood Cell Transfusions is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Iron Overload Due to Repeated Red Blood Cell Transfusions
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials